Leah Cordovez, MD
Internal Medicine · Nashville, TNNPI 1710100656
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $57,200 of the $63,709 with a category attached, or 89.8%. Amgen accounts for 97.1% of it on its own, with 22 other manufacturers making up the rest. Reporting peaked in 2022 at $37,030 and has fallen 99.8% since, to $83 in 2025. Among internal medicine clinicians in TN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 214 payments — averaging $297.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$62K
- AbbVie$903
- Lilly USA, LLC$131
- Novo Nordisk$117
- Harmony Biosciences LLC$98
- Jazz Pharmaceuticals Inc.$64
- plus $564 from 17 others
What the payments were for
- Speaking & faculty fees$57,20090%
- Travel & lodging$3,5476%
- Food & beverage$2,9495%
- Education$130%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 109 | $61,831 |
| AbbVie(2 entities) | 53 | $903 |
| Lilly USA, LLC | 8 | $131 |
| Novo Nordisk | 6 | $117 |
| Harmony Biosciences LLC | 4 | $98 |
| Jazz Pharmaceuticals Inc. | 3 | $64 |
| AstraZeneca | 4 | $57 |
| Idorsia Pharmaceuticals US Inc | 3 | $54 |
| Abbott | 3 | $50 |
| Inspire Medical Systems, Inc. | 1 | $46 |
| Exact Sciences | 2 | $41 |
| IBSA Pharma Inc. | 2 | $37 |
| Shield Therapeutics Inc | 2 | $36 |
| Eisai Inc. | 2 | $34 |
| Alkermes, Inc. | 2 | $29 |
| Alfasigma USA, Inc. | 2 | $29 |
| Pfizer | 2 | $28 |
| Astellas Pharma US Inc | 1 | $22 |
| Merck | 1 | $21 |
| Novartis | 1 | $21 |
| Dermira, Inc. | 1 | $20 |
| Sanofi-aventis U.S. LLC | 1 | $19 |
| Arbor Pharmaceuticals, Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$63,709 in reported general payments places this provider in the 95th percentile of 2,216 internal medicine providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 16 | $27,555 |
| Repatha SureclickEvolocumab | 24 | $12,664 |
| EliquisApixaban | 18 | $10,253 |
| OzempicSemaglutide | 12 | $9,936 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 12 | $1,128 |
| Valsartan | 14 | $715 |
| Levothyroxine Sodium | 29 | $372 |
| Atorvastatin Calcium | 17 | $326 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 14 | $322 |
| Gabapentin | 21 | $221 |
| Amlodipine Besylate | 17 | $197 |
| Montelukast Sodium | 16 | $167 |
| Zolpidem Tartrate | 12 | $96 |
| Prednisone | 11 | $59 |
| Metformin Hcl | 12 | $34 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $131 | $27,55516 claims |
| PfizerEliquis | $28 | $10,25318 claims |
| Novo NordiskOzempic | $117 | $9,93612 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,216 internal medicine providers in Tennessee.
Other internal medicine in Nashville
- John AndersonNashville$1.5M
- Temidayo AbeNashville$113K
- Wayne RileyNashville$86K
- Asad Al AboudNashville$44K
- Mark KouryNashville$41K
- David HeusinkveldNashville$24K
- Charlotte LohreyNashville$19K
- Malek Al-OmaryNashville$18K
- James GekasNashville$17K
- William LizarragaNashville$16K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.